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H I G H L I G H T S
• We aimed to identify novel P2X1 and P2X4 receptor ligands.
• We used a combination if in silico screening, ﬂuorescence and two-electrode voltage clamp.
• Only minor improvements in potency were achieved.
• We highlight the challenge of identifying compounds that target this receptor class.
• We suggest that at least two complimentary approaches are needed to conﬁrm novel hits.
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A B S T R A C T
Identifying novel small-molecule P2X1 and P2X4 ligands with sub-type speciﬁcity and high-aﬃnity remains a
pharmacological challenge. Here we use computational methods, electrophysiology and ﬂuorescent microplate
assays to screen for ligand candidates acting at these receptors. Modelling and docking identiﬁed 80 compounds
for testing at P2X4 receptors, and 20 of these showed>50% inhibition in ﬂuorescence-based assays, making
them appealing for further SAR studies. Conﬁrmation of activity by two-electrode voltage clamp, followed by
their elaboration resulted in only minor improvements in potency, with the highest IC50 being 295 μM. Testing
on P2X1 receptors, resulted in a series of biguanide compounds that yielded a maximum IC50 of 100 μM, but no
consistent SAR could be found. Potencies of established antagonists gave expected results, although the mea-
sured potencies varied between techniques and no antagonism could be found for compounds such as parox-
etine, carbamazepine, 9(10H)-acridanone, acridinol and phenoxazine-type heterocycles. This study highlights
the challenge of identifying P2X4 and P2X1 ligands and suggests that a combination of complimentary ap-
proaches is needed if we are to be conﬁdent of ligand activities at these receptors.
1. Introduction
There are seven P2X receptor subunits that can assemble into a
range of functional homomeric and heteromeric receptors. All are tri-
meric, transmembrane ligand-gated ion channels, the activation of
which opens a central ion-conducting pore and results in a wide range
of biological functions.
For P2X1 and P2X4 receptors there is still a clear clinical need for
selective ligands that has not been met. For example, the development
of P2X1 receptor-selective ligands could lead to the development of safe
and eﬀective treatments for the prevention of blood clotting, or in
combination with β–adrenergic antagonists, as non-hormonal male
contraceptives (White et al., 2013). In transgenic mice P2X1 knockout
blocks sympathetically mediated sperm transport through the vas de-
ferens and also causes a resistance to systemic thromboembolism. In
contrast, overexpression causes the mice to exhibit platelet hy-
perreactivity and thrombosis at high shear (Hechler et al., 2003; Oury
et al., 2003). For P2X4 receptors, a knockout mouse model revealed an
association between P2X4 and neuropathic pain, inﬂammatory-asso-
ciated pain and tactile allodynia (Tsuda et al., 2009; Tsuda et al., 2013).
Furthermore, P2X4 receptors are upregulated in neuronal injury or
inﬂammation (Tsuda et al., 2013). As neuropathic pain is often resistant
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to currently available analgesics, inhibition of P2X4 receptors could
therefore represent a new therapeutic target for its management (Jurga
et al., 2017). Increased P2X4 receptor activity has been shown to be
cardioprotective and to promote remyelination in a mouse model of
multiple sclerosis (Ralevic, 2015; Zabala et al., 2018). These ﬁndings
suggest that positive allosteric modulators of P2X4 will also have
therapeutic potential.
ATP is the native agonist of all P2X receptors and there are α,β- and
β,γ-meATP derivatives that have similar actions, revealing the im-
portance of the phosphate side-chain in agonist recognition. Several
weak, nucleotide and non-nucleotide antagonists have also been dis-
covered, but many of these are not selective for P2X receptor subtypes.
For example, BzATP activates P2X1, P2X4 and other subtypes, but is
also an antagonist of P2Y12 (Bianchi et al., 1999; Ding et al., 2003).
The large polysulfonated compound suramin also inhibits both P2X and
P2Y receptors, as well as other G-proteins and proteases such as HIV
reverse transcriptase and protein kinase C (Freissmuth et al., 1996;
Hensey et al., 1989; Jentsch et al., 1987). Suramin has also acted as a
lead structure for the development of additional P2X receptor in-
hibitors, including derivatives with nanomolar potency, such as NF-449
acting at P2X1 receptors (North and Jarvis, 2013). Other large, but low
aﬃnity antagonists such as PPADS have also acted as lead structures,
but these derivatives similarly antagonise several subtypes, including
P2X1 and P2X4, among others (Syed and Kennedy, 2012).
Since antidepressants were found to be eﬀective against neuropathic
pain, a number of the compounds have been tested for inhibitory po-
tency at the P2X4 receptor, with Paraxetine being identiﬁed as an al-
losteric modulator (Fig. 1). A similar allosteric mechanism has been
proposed for 5-BDBD, although a competitive mechanism has also been
suggested (Balazs et al., 2013; Muller, 2015). The heterocyclic com-
pound phenoxazine was once used as a fabric dye, and its structure has
acted as a lead for P2X4 antagonists and a library of N-substituted
derivatives. The structure of the most active compounds, PSB-12054
(Fig. 1) and PSB-12062, inhibited P2X4 receptors with nanomolar po-
tency, but also showed activity at other P2X receptor subtypes
(Hernandez-Olmos et al., 2012). The heterocyclic anticonvulsant car-
bamazepine and its derivatives are also reported as potent P2X4 re-
ceptor antagonists and the most potent in this series (N,N-diisopro-
pylcarbamazepine) is also described as having allosteric behaviour.
More recently, BX430 was discovered, and was again described as an
allosteric modulator that lacks subtype speciﬁcity. However, unlike
many of the previous reports, a range of methods was used to validate
its mechanism of action, including patch clamp and calcium imaging
(Ase et al., 2015).
The relatively small number of commercially available, small, po-
tent, P2X1 and P2X4 subtype-selective ligands highlights the challenge
of targeting these receptors. In recent years attempts to identify new
P2X1 and P2X4 ligands has seen some successes. Here we describe our
eﬀorts to screen for P2X1 and P2X4 ligands and report on the chal-
lenges we faced. For the majority of hits identiﬁed using a ﬂuorescence-
based approach, we were unable to measure consistent responses in
subsequent electrophysiological assays. Furthermore, although some
well-established inhibitors were active in both assays, for several more
recently disclosed compounds, neither of our assays was able to re-
produce the inhibition that was previously reported. We therefore
conclude that screening programs should include a range of methods to
validate hits.
2. Methods
2.1. Computational modelling
A human homology model was created from the co-crystal structure
of ATP with zebraﬁsh P2X4 (4DW1; Hattori & Goaux, Nature 485 207-
212. 2012) and was assessed (B-factors, Ramachandran compliance).
The homology model was built within MOE 2015.10, using the
canonical human P2XA sequence Q99571. The direction of side-chains
of variant residues within 5 Å of ATP (G142, R142 and A292) was
maintained by holding the backbone atoms in the same positions and
the model subsequently relaxed by minimisation. The model was
checked for consistency using Ramachandran analysis and had 96.27%
of resides in favoured positions, a MolProbity Score of 1.87, and an
alignment of 0.316Å RSMD versus the 4DW1 structure.
The water map from 4DW1 was transferred and the system was
relaxed. Pocket waters were analysed, and those which bridged ATP
interactions were retained, and those that did not were removed. B-
Factor analysis showed these to be no less labile than the average for
the structure.
The virtual screening cascade was built of the following steps: 1)
assess and prepare suitable 3D structural information, 2) design and
screen pharmacophores as a pre-screening step, 3) conduct docking
based on pharmacophore outputs, 4) analysis and clustering, 5) med-
icinal chemistry appraisal and, 5) purchase.
An internal VS library (“SUNdb”) was deployed in this VS cascade,
containing over 1.8 million compounds from preferred suppliers with a
high level of content trust (Fig. 2). SUNdb is pre-ﬁltered for both PAINS
and other undesirable features using internal proprietary ﬁltering sys-
tems, with ﬁltration performed in Knime (Knime AG, 8005 Zurich,
Switzerland).
Pharmacophore pre-screening was conducted using two Boolean
pharmacophores; one based on the ATP interactions (5 features with a
minimum of 4 required) and a global pocket pharmacophore (29 fea-
tures with a minimum of 5 required). Both pharmacophores were
conducted with void spacing around the protein. This approach was
designed to create two hit sets; one with a similar binding mode to ATP,
and a second with a very diverse library of moieties that are predicted
to bind with more generally. Given that the binding pocket is sig-
niﬁcantly open to solvent, the diverse pharmacophore would require
signiﬁcant ﬁltering to ensure that the pharmacophore passes were ra-
tional.
The output of the pharmacophore screen was docked into the
human P2X4 homology model with conserved waters. For the ATP-
mode mimetic materials, docking was conducted by pharmacophore
placement. Pharmacophore screening and docking was conducted in
MOE 2015.10 using customised ﬂexible docking protocols (MOE,
Chemical Computing Group, QC H3A 2R7, Montreal, Canada).
Post-docking analysis and clustering allowed 100 exemplars of
docked materials from each pharmacophore mode to be assessed by
medicinal chemists, with a total of 80 materials selected for purchase.
Due to the nature of the diversity, the clustering was reasonably severe,
meaning that there was a high dissimilarity between centroids of the
clusters. A result of diversity means that any hit would likely be a
singleton, and so each cluster was held aside for follow up purchasing
or synthesis.
2.2. Compounds
Screening compounds were bought commercially from IOTA
Pharmaceuticals (Cambridge, UK), ChemBridge (San Diego, CA, USA),
Sigma Aldrich (St Loius, MO, USA) or were synthesised de novo ac-
cording to published procedures (Hernandez-Olmos et al., 2012).
2.3. Cell culture & receptor expression
Human P2X1 (Accession: P51575) or human P2X4 (Accession:
Q99571) subunit cDNA was cloned into pGEMHE for oocyte expression.
cRNA was in vitro transcribed from linearised plasmid cDNA template
using the mMessage mMachine Ultra T7 Transcription kit (Ambion,
Austin, Texas, USA). Stage V and VI oocytes were injected with 50 nl of
100–200 ng/μl cRNA (5–25 ng injected), and currents were recorded
1–4 days post-injection.
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Fig. 1. Compounds reported to have activity at P2X4 receptors.
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2.4. Cell lines
Human embryonic kidney (HEK) 293T cells were grown on 90mm
round tissue culture plates as monolayers in DMEM/F12 (Life
Technologies) supplemented with 10% foetal bovine serum (FBS; Sigma
Aldrich) at 37 °C in a moist atmosphere containing 5% CO2.
A HEK293T cell-line stably expressing hP2X1 receptors was con-
structed by transducing with pLV-tTR-Krab-Blast to create the HEK293-
tTR-Krab-Blast cell line. After selection of transduced cells with
Blasticidin, this cell line was transduced with pLV-P2X1-IRES.IFP1.4 to
create the inducible hP2X1-FLAG-IRES-IFP1.4 cell line that was clonally
selected for high expression (Ruepp et al., 2015).
HEK293T cells expressing P2X4 receptors were made by transient
transfection of cDNA using polyethyleneimine (PEI: 25 kDa, linear,
powder, Polysciences Inc., Eppelheim, Germany). In brief, 30ml of PEI
(1 mgml−1), 5 mg cDNA and 1ml DMEM/F12 were incubated for
10min at room temperature, added dropwise to a 90mm plate of
70–80% conﬂuent HEK293T cells, and incubated for 2–3 days before
use.
2.5. Fluorometric microplate assays
Assays were performed using methods similar to those described
elsewhere (Thompson et al., 2010). In brief, fragments were assessed
for both agonist and antagonist activities using HEK293T cells expres-
sing P2X receptors incubated for 45min with 50 μl of a ﬂuorescent
membrane potential (dye FLIPR Membrane Potential Assay Kit, Mole-
cular Devices, Wokingham, UK) dissolved in buﬀer (mM: 115 NaCl, 1
KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, 10 D-Glucose, pH 7.4). Dye-loaded
cells were transferred to a FlexStation III (Molecular Devices) where
compound applications were made without removing the dye. At
recording intervals of 1.2 s, baseline ﬂuorescence was recorded for 20 s,
followed by a further 60 s after the addition of compounds. Ultimately
two applications were made to the same cells. In the ﬁrst of these
agonist activity was assessed by adding 50 μl novel fragment (ﬁnal
concentration=300 μM) to each well. Following the completion of the
ﬁrst application, a second 50 μl application of 30 μM ATP (ﬁnal con-
centration=10 μM) was then added to the same cells. A response upon
the ﬁrst (fragment) application and an absence of a response on the
second (ATP) application indicated agonist activity followed by in-
hibition as a result of receptor desensitisation. In contrast, an antagonist
did not elicit a response in the ﬁrst application and inhibited the sub-
sequent ATP response. The absence of a response during the ﬁrst ap-
plication and a robust ATP response upon the second application in-
dicated that the fragment was inactive.
In addition to testing fragments, the reproducibility of each ex-
periment was assessed by including an ATP concentration-response in
the ﬁrst column and a saline control in the last column of the ﬁrst
application. This ensured ATP activation at appropriate concentrations
at the start of the experiment and that buﬀer alone did not alter the
baseline ﬂuorescence. The saline control in the ﬁrst application also
meant that an ATP concentration-response could be performed at the
end of the second application. This allowed cell viability to be assessed
by comparing the ATP concentration-response at the start of the ﬁrst
application with the ATP concentration-response at the end of the
second application. At least two replicates were performed and com-
pounds scored as hits when activity was observed on two plates.
Following the identiﬁcation of active compounds from these single-
concentration screens, the same procedure was used to subsequently
test hits for concentration-dependence to conﬁrm their activity and to
obtain a measure of their potency. Measurements from these con-
centration-dependence experiments were ﬁtted using Equ 1 below.
Fig. 2. Flow chart of compound survival (number of compounds in brackets) during each stage of the in silico screen.
Fig. 3. ATP bound to the P2X4 co-crystal
structure (4DW1), and examples of two
docked poses (57 and 66). Upper panels
show cartoon representations of each pose,
and the lower panels are ligand interaction
diagrams. The circle highlights the binding
site that is shown in panels B and C. (A) In
4DW1 the purine interacts with the back-
bones of K67 and T186, and the α, β and γ
phosphates with S289, K313 and R295 re-
spectively. (B) For 57 the ether oxygen in-
teracts with K69 and the amine with the
backbone of L214. The two aromatic rings
are ﬂanked by the sidechains of K67, K69,
L188, I223, and I229. (C) The imidazole in
66 undergoes π-stacking with H140, the
alcohol is stabilised by a backbone interac-
tion with K215, and the aromatic ring is
located in a hydrophobic groove created by
K67, K69, L188 and I229.
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Table 1
Single point FMA screening on hP2X4 stably expressed in HEK293T cells. Test
fragments were identiﬁed from an in silico screen of an hP2X4 homology model
that was based on the zebraﬁsh P2X4-ATP co-crystal structure (4DW1).
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
1 0.50 ± 0.19 3 0.63 ± 0.07 4
2 0.36 ± 0.01 3 0.51 ± 0.04 4
3 0.53 ± 0.02 3 0.31 ± 0.05 3
4 0.75 ± 0.08 3 0.57 ± 0.06 4
5 0.77 ± 0.09 3 0.27 ± 0.07 3
6 0.64 ± 0.09 3 0.44 ± 0.11 4
7 0.61 ± 0.07 3 0.29 ± 0.10 3
8 0.67 ± 0.16 3 0.46 ± 0.09 4
9 0.65 ± 0.08 3 0.38 ± 0.09 4
10 0.39 ± 0.03 3 0.43 ± 0.1 4
11 0.80 ± 0.08 3 0.36 ± 0.08 4
12 0.47 ± 0.09 3 0.08 ± 0.09 3
13 1.06 ± 0.08 3 0.43 ± 0.11 4
14 0.42 ± 0.09 3 0.27 ± 0.08 4
Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
15 0.78 ± 0.05 3 0.36 ± 0.11 4
16 0.77 ± 0.13 3 0.36 ± 0.08 4
17 0.70 ± 0.05 3 0.35 ± 0.06 3
18 0.49 ± 0.19 3 0.35 ± 0.09 4
19 0.71 ± 0.13 3 0.33 ± 0.03 4
20 0.12 ± 0.05 3 0.10 ± 0.04 4
21 0.35 ± 0.11 3 0.12 ± 0.03 4
22 0.44 ± 0.09 3 0.26 ± 0.08 3
23 0.41 ± 0.08 3 0.45 ± 0.11 3
24 0.49 ± 0.14 3 0.53 ± 0.08 3
25 0.58 ± 0.06 3 0.53 ± 0.07 3
26 0.66 ± 0.07 3 0.51 ± 0.06 3
27 0.77 ± 0.04 3 0.47 ± 0.05 3
(continued on next page)
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Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
28 0.77 ± 0.05 3 0.44 ± 0.06 3
29 0.83 ± 0.08 3 0.58 ± 0.03 3
30 0.44 ± 0.07 3 0.60 ± 0.11 3
31 0.66 ± 0.07 3 0.46 ± 0.03 3
32 0.29 ± 0.14 3 0.52 ± 0.06 3
33 0.64 ± 0.21 3 0.41 ± 0.04 3
34 0.35 ± 0.10 3 0.14 ± 0.03 3
35 0.05 ± 0.02 3 0.28 ± 0.12 3
36 0.81 ± 0.13 3 0.48 ± 0.04 3
37 0.58 ± 0.05 3 0.56 ± 0.11 3
38 0.31 ± 0.28 3 0.22 ± 0.10 3
39 0.68 ± 0.01 3 0.24 ± 0.16 3
Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
40 0.64 ± 0.05 3 0.69 ± 0.30 3
41 0.82 ± 0.04 3 0.62 ± 0.09 3
42 0.76 ± 0.06 3 0.65 ± 0.10 3
43 0.76 ± 0.08 3 0.46 ± 0.07 3
44 0.64 ± 0.09 3 0.47 ± 0.11 3
45 0.71 ± 0.06 3 0.56 ± 0.07 3
46 0.67 ± 0.02 3 0.32 ± 0.11 3
47 0.62 ± 0.05 3 0.64 ± 0.23 3
48 0.62 ± 0.07 3 0.45 ± 0.22 3
49 0.82 ± 0.09 3 0.56 ± 0.09 3
50 0.58 ± 0.11 3 0.74 ± 0.39 3
63 0.67 ± 0.12 3 0.60 ± 0.03 3
52 0.79 ± 0.06 3 0.46 ± 0.05 3
53 0.56 ± 0.09 3 0.29 ± 0.06 3
(continued on next page)
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Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
54 0.93 ± 0.08 3 0.68 ± 0.03 3
55 0.49 ± 0.05 3 0.80 ± 0.01 3
56 0.51 ± 0.06 3 0.30 ± 0.03 3
57 0.21 ± 0.21 3 0.57 ± 0.13 3
58 0.59 ± 0.11 3 0.50 ± 0.08 3
59 0.71 ± 0.15 3 0.41 ± 0.05 3
60 0.75 ± 0.03 3 0.61 ± 0.01 3
61 0.65 ± 0.09 3 0.67 ± 0.03 3
62 0.59 ± 0.06 3 0.82 ± 0.05 3
63 0.61 ± 0.40 3 0.62 ± 0.02 3
64 0.23 ± 0.19 3 0.72 ± 0.10 3
65 0.72 ± 0.12 3 0.69 ± 0.10 3
66 0.30 ± 0.11 3 0.65 ± 0.11 3
67 0.75 ± 0.08 3 0.46 ± 0.02 3
Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
68 0.71 ± 0.06 3 0.69 ± 0.01 3
69 0.72 ± 0.07 3 0.67 ± 0.05 3
70 0.62 ± 0.09 3 0.64 ± 0.03 3
71 0.56 ± 0.09 3 0.70 ± 0.01 3
72 0.60 ± 0.10 3 - -
73 0.65 ± 0.10 3 0.39 ± 0.07 3
74 0.88 ± 0.08 3 - -
75 0.81 ± 0.07 3 - -
76 0.72 ± 0.10 3 - -
77 0.87 ± 0.06 3 - -
78 0.49 ± 0.08 3 - -
79 0.51 ± 0.09 3 - -
(continued on next page)
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Applying novel compounds and a known agonist to the same cells
had several advantages, namely that 1) agonist, antagonist and allos-
teric modulators were identiﬁed in a single screen, 2) which reduced
material costs, 3) the 16min time period between the ﬁrst and second
applications allowed fragments to equilibrate in the presence of the
cells before the second ATP application was added and, 4) reproduci-
bility was improved because the same cells were subjected to both
applications.
2.6. Oocyte maintenance
Oocytes from Xenopus laevis were purchased from EcoCyte
Bioscience (Castrop-Rauxel, Germany) and stored at 16 °C in ND96
(96mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.5).
2.7. Electrophysiology
Using two electrode voltage clamp (TEVC), Xenopus oocytes were
routinely clamped at −60 mV using an OC-725 ampliﬁer (Warner
Instruments, Connecticut, USA), NI USB-6341 X Series DAQ Device
(National Instruments, Berkshire, UK) and the Strathclyde
Electrophysiology Software Package v4.7.3 (University of Strathclyde,
UK). Micro-electrodes were fabricated from borosilicate glass
(GC120TF-10, Harvard Apparatus, Edenbridge, Kent, UK) using a two
stage horizontal pull (P-1000, Sutter Instrument Company, California,
USA) and ﬁlled with 3M KCl. Pipette resistances ranged from 0.8 to
2.0 MΩ. Oocytes were placed in a perfusion chamber made from 2mm
wide x 30mm long silicon tubing that was cut in half lengthways (total
volume∼ 0.1ml), and were perfused with ND96 at a rate of
12mlmin−1. Drug application was via a simple gravity fed system
calibrated to run at the same rate. For inhibition curves, antagonists
were routinely co-applied in the presence of either 0.5 μM ATP (EC50 of
hP2X1) or 3 μM ATP (EC50 of hP2X4), or continuously applied for 1min
before the co-application of these ATP concentrations. A 4min wash
was used between drug applications for hP2X1 and 3min for P2X4.
2.8. Data analysis
Measurements from the FlexStation III were recorded using the in-
tegrated software SoftMax Pro v5.4.5 (Molecular Devices). Analysis of
concentration-dependence was performed with GraphPad Prism v5.00
(GraphPad Software, San Diego, CA, USA). Peak ﬂuorescence was
measured at a range of ligand concentrations and normalised to the
maximum peak ﬂuorescence for the same experiment. The mean and
S.E.M. for a series of oocytes was plotted against agonist or antagonist
concentration and iteratively ﬁtted to the following equation:
= +
−
+
−
y I F F
1 10 R x
min
max min
log( )nH50 (Equ. 1)
where Fmin is the baseline ﬂuorescence, Fmax is the peak ﬂuorescence,
R50 is the concentration of ligand needed to generate a half-maximal
response, x is the ligand concentration and nH is the Hill slope.
For electrophysiological measurements, peak current responses
were measured across a range of concentrations and normalised to the
maximum peak current for the same oocyte. The mean and S.E.M. for a
series of oocytes was plotted against agonist or antagonist concentra-
tion and iteratively ﬁtted to the following equation using GraphPad
Prism v5.00:
= +
−
+
−
y I I I
1 10 EC x
min
max min
log( )nH50 (Equ. 2)
where Imin is the baseline current, Imax is the peak current evoked by
agonist, EC50 is the concentration of agonist needed to evoke a half-
maximal response, x is the ligand concentration and nH is the Hill slope.
For single-point assays 300 μM of test compound was co-applied in
the presence of ATP and the peak current responses normalised to the
peak current response in the presence of ATP alone. Based upon a
simple antagonist mechanism of action (nH=1), the single point
measurement was used to predict the IC50 based on Equ 2.
3. Results
Computational modelling and ligand docking into hP2X4 receptors
initially identiﬁed 80 compounds that were available from the IOTA
fragment library (Fig. 3). These fragments formed a diverse group, with
scaﬀolds largely represented by a series of heterocyclic compounds.
Single-point FMA screening of these 80 fragments on hP2X4 yielded the
data shown in Table 1. For the majority of these compounds, single-
point FMA assays were also performed on hP2X1 receptors to probe for
receptor selectivity (Table 1).
Of the 80 fragments identiﬁed from in silico docking into hP2X4, 20
fragments reached the 50% inhibition threshold that was used to pro-
gress hits for further study. For these, the ten highest potency com-
pounds were also tested by two-electrode voltage clamp on hP2X4 at a
single concentration of 300 μM (Table 2). The results obtained with the
Table 1 (continued)
Compound
hP2X4 hP2X1 Structure
F/Fmax n F/Fmax n
80 0.47 ± 0.09 3 - -
Fragments denoted with ‘-’ were not tested on hP2X1 receptors owing to their
limited availability.
Table 2
The top ten most potent hP2X4 ligands identiﬁed using single-point FMA screens, and subsequently validated with single-point TEVC assays.
hP2X4 hP2X1
Identiﬁer FMA (F/Fmax) n TEVC (I/Imax) n FMA (F/Fmax) n TEVC (I/Imax) n
2 0.36 ± 0.01 3 1.19 ± 0.24 3 0.51 ± 0.04 4 1.10 ± 0.03 3
20 0.12 ± 0.05 3 0.95 ± 0.15 3 0.10 ± 0.04 4 0.72 ± 0.04 4
21 0.35 ± 0.11 3 0.95 ± 0.04 3 0.12 ± 0.03 4 0.52 ± 0.04 3
32 0.29 ± 0.14 3 1.15 ± 0.04 3 0.52 ± 0.06 3 0.57 ± 0.02 4
34 0.35 ± 0.10 3 0.78 ± 0.08 3 0.14 ± 0.03 3 0.08 ± 0.03 3
35a 0.05 ± 0.02 3 0.00 ± 0.00 3 0.28 ± 0.12 3 0.44 ± 0.02 4
38a 0.31 ± 0.28 3 2.49 ± 0.28 6 0.22 ± 0.10 3 1.01 ± 0.06 3
57a 0.21 ± 0.21 3 0.31 ± 0.10 3 0.57 ± 0.13 3 0.66 ± 0.01 4
64 0.23 ± 0.19 3 1.74 ± 0.24 3 0.72 ± 0.10 3 1.02 ± 0.04 3
66a 0.30 ± 0.11 3 0.31 ± 0.05 3 0.65 ± 0.11 3 0.95 ± 0.12 3
a These fragments yielded changes to the hP2X4-mediated response in both FMA and TEVC assays and were subjected to further testing (Fig. 3).
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Fig. 4. Eﬀects of selected fragments on hP2X4, measured using TEVC. (A-D) Concentration-dependent eﬀects of selected fragments on the 3 μM ATP response. (E)
Eﬀects of the same fragments on uninjected oocytes, showing that 300 μM 38, 57 and 66 have no measureable eﬀects, while 300 μM 35 causes a hyperpolarising
response. (F) The hyperpolarising eﬀect of 30 μM 35 was evident immediately before the depolarising current evoked by ATP (note the small upward deﬂection of the
trace) and is likely to be responsible for the apparent reduction in the amplitude of the depolarising ATP response. This summation of the two eﬀects could be
mistaken for hP2X4 receptor inhibition.
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TEVC assay were not consistent with the FMA data as only 35, 57 and
66 consistently inhibited the agonist response in both assays, and the
remaining seven compounds produced no inhibition of the P2X4
mediated current. Two of these seven compounds (38 and 64) produced
a signiﬁcant potentiation of the TEVC response despite indicating in-
hibition using FMA. For the three compounds that consistently in-
hibited hP2X4 receptors at 300 μM, IC50 values were determined by
measuring concentration-dependent inhibition by TEVC (Fig. 4A – 4D).
To test for non-speciﬁc eﬀects we also tested these fragments on un-
injected oocytes at 300 μM. Compounds 38, 57 and 66 had no eﬀect,
while 300 μM 35 caused a hyperpolarising current that indicated oﬀ-
target eﬀects (Fig. 4E). This could be mistaken for hP2X4 inhibition as it
would reduce the amplitude of the ATP-evoked current (Fig. 4F). It is
noteworthy that 35 contains a number of structural elements that can
cause assay interference, namely nitro-phenyl and dicyanobenzyl
groups, and this could be the case here. Hence this fragment was not
considered as a genuine hit for further investigation. Single-point TEVC
measurements of the same ten fragments on hP2X1 revealed only minor
diﬀerences in compound activities when compared to hP2X4, with the
only diﬀerence being 34 which displayed almost complete inhibition of
hP2X1 and only limited eﬀects on hP2X4.
To evaluate the potential of the initial hit fragments to become leads
for future hP2X4 drug discovery, six compound series were identiﬁed
for further evaluation based on (a) encouraging activity in both the
FMA and TEVC assays or, (b) activity in the FMA assay and structural
similarity to reported hP2X4 ligands. The primary objective of the ex-
ercise was to establish if robust structure-activity relationships (SAR)
could be established and positions within the molecule identiﬁed that
would allow future elaboration to increase potency and selectivity.
Additional considerations regarding physicochemical properties were
also important in the choice of compounds for testing, and molecules
with high lipophilicity, high polarity, large aromatic ring count and
known structural alerts were avoided. For this initial exercise, com-
mercially available compounds were selected with either a high degree
of similarity to the initial hit fragments to eliminate false positives and
singletons, or with the scaﬀold substituted at key sites to probe for
additional binding site regions that could increase potency. Given the
absence of structural information at the time the work was performed,
robust pharmacophore analogues with as many diverse single sub-
stitutions were selected. In certain cases no suitable analogues were
commercially available and key molecules were synthesised to com-
plement the sets.
First priority was given to those compounds that showed promising
activity in both FMA and TEVC screening formats. From this, three
groups were considered worthy of further consideration. These in-
cluded a series of amines represented by 20, 21 and 22, a series of
diarylmethanes represented by 30 and 66, and a series of diaryl
Table 3A
Elaboration of initial hit fragments 20, 21 and 22, and assessment using single
point TEVC assays on oocyte-expressed hP2X4.
Identiﬁer I/Imax n Structure
81 0.66 ± 0.06 4
82 0.70 ± 0.08 3
83 1.28 ± 0.05 4
84 1.29 ± 0.23 3
85 0.82 ± 0.04 7
86 1.02 ± 0.10 3
87 1.22 ± 0.13 4
88 1.07 ± 0.10 6
Table 3B
Further elaboration of initial hit fragments 20, 21 and 22, and assessmentusing
single point TEVC assays on oocyte-expressed hP2X4.
Identiﬁer I/Imax n Structure
89 0.83 ± 0.06 7
90 0.97 ± 0.01 3
91 0.95 ± 0.10 3
92 1.20 ± 0.08 5
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heterocycles represented by 32 and 34.
Second priority was given to fragments that shared structural si-
milarity to previously reported hP2X4 ligands but only showed activity
with FMA. Two additional groups were selected in this category, in-
cluding a series of indole-derived molecules based on the tetracyclic hit
10 and the structurally related hits 7, 9, 12, 13 and 16. As well as being
a cluster of related hits, these molecules shared some features with
carbamazepine (Fig. 1). A series of carbamates and ureas represented
by 41, 48 and 64, were structurally similar to the P2X4 modulator BX
430 (Fig. 1), and were also selected.
Despite the encouraging activity observed with 20, 21 and 22,
TEVC testing of close analogues failed to identify compounds with en-
couraging activity proﬁles (Table 3A). Indeed, the majority of analo-
gues tested were inactive. To be conﬁdent of the results, the original
fragments (1 - 80) were analysed and found to be of a high degree of
purity. In addition, freshly synthesised material prepared in our la-
boratory demonstrated a similar level of activity when tested, con-
ﬁrming the original observations. To further investigate the structural
basis for the loss of activity in the close analogues, a series of new
compounds were chosen with close structural similarity to the original
hit fragments. This resulted in a further set of compounds in which the
second ring of the bicyclic core was removed (Table 3B). However, this
series also failed to identify any compounds with suﬃcient activity for
further progression. A series of analogues inspired by 30, 32 and 66
also had no activity (Table 3C) as did structural analogues of 41, 48 and
64 (Table 3D).
Fragment 10 initially produced an encouraging response when
tested with FMA, and given the structural similarity to compounds such
as carbamazepine, represented an attractive start point for further
evaluation. From a medicinal chemistry perspective, the tetracyclic
nature of the molecule was not attractive and consideration was given
to removing this element in analogues selected for screening. It was also
proposed that analogues should replace the indole with benzimidazole
as the incorporation of the additional nitrogen atom would potentially
increase solubility and additionally oﬀer a further H-bond acceptor. At
total of 39 structurally related analogues were selected for testing
(Table 3E). The ﬁrst of these, 146, showed encouraging activity in FMA
assays, as did the analogues 149 and 169 in which aromatic groups
were appended to the amino group. Unfortunately, a more expanded
SAR failed to identify further improvements and when tested in TEVC
assays none of these compounds demonstrated activity, indicating that
they were false positives.
Following this failure to identify robust hits it was decided to test
representatives of structural chemotypes not represented within the
library. We consequently tested a range of 15 biguanide compounds
Table 3C
Elaboration of initial hit fragments 30, 32 and 66, and assessment using single
point TEVC assays on oocyte-expressed hP2X4.
Identiﬁer I/Imax n Structure
93 1.42 ± 0.07 3
94 1.03 ± 0.04 4
95 1.10 ± 0.03 3
96 1.04 ± 0.07 3
97 1.01 ± 0.01 3
98 1.04 ± 0.12 3
99 1.01 ± 0.26 3
100 1.02 ± 0.11 3
101 0.97 ± 0.03 3
102 1.03 ± 0.13 4
103 1.01 ± 0.11 3
104 0.95 ± 0.01 3
Table 3C (continued)
Identiﬁer I/Imax n Structure
105 1.24 ± 0.08 3
106 1.41 ± 0.04 3
107 1.02 ± 0.09 4
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Table 3D
Elaboration of initial hit fragment 10, and assessment using single point TEVC
assays on oocyte-expressed hP2X4.
Identiﬁer I/Imax n Structure
108 0.90 ± 0.10 3
109 1.21 ± 0.17 4
110 0.59 ± 0.11 4
111 1.23 ± 0.08 5
112 1.01 ± 0.10 4
113 0.99 ± 0.11 3
114 1.06 ± 0.07 3
115 1.07 ± 0.03 4
116 1.19 ± 0.05 3
117 0.93 ± 0.02 3
118 1.08 ± 0.30 3
119 0.82 ± 0.05 3
Table 3D (continued)
Identiﬁer I/Imax n Structure
120 0.98 ± 0.14 3
121 0.88 ± 0.07 3
122 0.77 ± 0.13 3
123 0.89 ± 0.06 5
124 0.76 ± 0.05 5
125 1.38 ± 0.13 4
126 1.43 ± 0.10 5
127 0.80 ± 0.06 4
128 0.93 ± 0.09 2
129 0.74 ± 0.01 3
130 0.65 ± 0.05 3
131 1.05 ± 0.13 3
132 1.10 ± 0.10 3
133 0.53 ± 0.03 3
134 0.79 ± 0.02 3
(continued on next page)
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and derivatives that were remaining from previous screening cam-
paigns. We measured activities by concentration-response using TEVC
on hP2X1 and found encouraging results from our initial screens
(Table 4). Compounds with activity showed highly reproducible in-
hibition, with the lowest IC50 value being 100 μM for 216 (Fig. 5).
However, no further improvements in inhibitory activity or consistent
SAR could be seen in the series and no other compounds were explored.
The lack of activity that we observed with these diﬀerent series of
compounds also prompted us to investigate the potency of ligands that
were previously reported to inhibit the hP2X4 receptor. One such li-
gand, that was previously reported by Nippon Chemiphar to be a mi-
cromolar antagonist of hP2X4, was synthesised and given the name
UoS14919 (Fig. 1) (Ushioda, Kobayashi, Saito, Sakuma, Imai & Inoue).
UoS14919 was ﬁrst tested using FMA and inhibited the hP2X4 agonist
response with an IC50 of 61 nM (Fig. 6A). In TEVC, co-application of
ATP with 10 μM UoS14919 did not inhibit hP2X1 (Imax= 0.96 ± 0.04,
Table 3D (continued)
Identiﬁer I/Imax n Structure
135 0.98 ± 0.08 3
136 0.77 ± 0.07 3
137 0.72 ± 0.05 3
138 1.09 ± 0.13 3
139 0.86 ± 0.09 3
140 0.84 ± 0.12 3
141 0.87 ± 0.08 3
142 0.41 ± 0.05 3
143 1.04 ± 0.05 3
144 0.89 ± 0.03 3
145 1.07 ± 0.01 3
Table 3E
Probing the indole substructure of initial hit fragment 10 by single point TEVC
assays on oocyte-expressed hP2X4.
Identiﬁer I/Imax n Structure
146 0.67 ± 0.03 4
147 1.16 ± 0.09 5
148 1.19 ± 0.10 4
149 0.52 ± 0.05 4
150 0.65 ± 0.12 4
151 0.66 ± 0.05 5
152 0.84 ± 0.05 5
153 0.88 ± 0.13 2
154 0.78 ± 0.07 6
155 1.01 ± 0.06 3
156 1.05 ± 0.09 3
157 0.97 ± 0.04 3
158 0.92 ± 0.06 3
159 0.8 ± 0.05 6
160 1.05 ± 0.06 3
(continued on next page)
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Table 3E (continued)
Identiﬁer I/Imax n Structure
161 1.03 ± 0.20 3
162 1.17 ± 0.31 3
163 0.85 ± 0.02 3
164 1.12 ± 0.16 4
165 1.40 ± 0.13 6
166 1.23 ± 0.13 3
167 1.09 ± 0.16 6
168 1.24 ± 0.25 5
169 0.63 ± 0.04 5
170 0.97 ± 0.05 3
171 0.94 ± 0.10 3
172 0.93 ± 0.02 3
173 0.75 ± 0.04 3
174 1.00 ± 0.04 3
Table 3E (continued)
Identiﬁer I/Imax n Structure
175 0.94 ± 0.04 3
176 1.18 ± 0.19 3
177 1.26 ± 0.09 3
178 1.23 ± 0.02 3
179 1.38 ± 0.17 3
180 0.96 ± 0.06 3
181 0.84 ± 0.16 3
182 0.94 ± 0.07 3
183 0.85 ± 0.010 3
184 0.97 ± 0.02 3
185 0.74 ± 0.03 3
186 0.92 ± 0.03 3
(continued on next page)
P. Beswick, et al. Neuropharmacology 157 (2019) 107674
14
n=3), but caused 50% inhibition of hP2X4 (Imax= 0.50 ± 0.13,
n=3). A 30 s pre-application of UoS14919 further increased potency at
hP2X4, as shown by the total and reversible inhibition at the same
10 μM concentration (Fig. 6B). Because of the high aﬃnity of this
compound it was not possible to make equilibrium measurements using
TEVC and no concentration-response measurements were undertaken
using this technique.
Two further compounds have been reported by Hernandez-Olmos
et al. (Hernandez-Olmos et al., 2012). These are phenoxazine (PSB-
12054; IC50; hP2X4=0.19 μM; hP2X1=6.52 μM) and acridinol (IC50;
hP2X4=2.44 μM, hP2X1=0.60 μM) (Fig. 1). Limited solubility dic-
tated that these compounds could be maximally applied at concentra-
tions of 75 μM and 93 μM respectively, concentrations that should result
in complete inhibition. However, neither of these compounds showed
any appreciable inhibition using either FMA or TEVC when either co-
applied or pre-applied for 1min (Fig. 6C). Other reported hP2X4 an-
tagonists such as carbamazepine, paroxetine, and 9(10H)-acridanone
similarly did not show agonist or antagonist activities in our FMA and
TEVC assays (Fig. 1). In contrast, the established ligands NF449 and
suramin both caused inhibition (data not shown).
4. Discussion
Here we report the use of fragment-based drug discovery to screen
for ligands acting at hP2X4 receptors. This resulted in low potency hits
that were conﬁrmed by TEVC to have a maximum IC50 of 295 μM.
Further elaboration of these lead compounds did not result in the an-
ticipated increases in activity that we have previously seen at other
receptors (Thompson et al., 2010; Thompson et al., 2013; Verheij et al.,
2012). There were also inconsistencies in the results obtained using
FMA with voltage-sensitive dyes and electrophysiological recordings
using TEVC, the latter of which is the gold-standard for measuring the
eﬀects of compounds on ion channels. Using TEVC we were also able to
show inhibition by several well-established antagonists, but were un-
able to reproduce the antagonism reported for compounds that have
been identiﬁed more recently using calcium-based ﬂuorescent assays
(Hernandez-Olmos et al., 2012).
Our most potent hit structures are very diﬀerent from classic P2X
ligands, such as nucleotide analogues BzATP, non-hydrolysable ATP
derivatives, sulfonated dye compounds (suramin, NF-449) and pyr-
idoxal phosphate congeners (PPADS). All of these compounds are non-
selective and often highly charged, and therefore diﬃcult to develop
into pharmacologically useful compounds. Instead, our hit structures
are small and more drug-like heterocyclic compounds that could re-
present more reasonable starting points for further synthetic optimisa-
tion. However, in our current study, an extensive investigation of po-
tential SAR failed to identify any robust series. Such a ﬁnding is
disappointing as there are several promising structures within the sets.
For example, those in Tables 3D and 3E contain an indole or benzimi-
dazole core in some instances fused to a six membered ring, templates
that are common in pharmacologically active molecules that are well
characterised and with proven mechanisms of action. This is an at-
tractive feature that was the key driver in the selection of this structure
for further work, while the precedence of similar active molecules in
the literature indicates that any identiﬁed hits would not be false-po-
sitives resulting from assay interference. A lack of SAR therefore sug-
gests the inﬂuence of biological phenomena such as the original hits
already being optimally bound to a low aﬃnity site or non-spcecifc
interactions that are not reproduced in the analogues. Other reasons
could include the precence of trace impurities that were present in the
original hits, but we believe that this is unlikley as hit compounds were
thoroughly analysed upon receipt and several were resynthesied and
retested. Other examples of promising structures included compounds
such as 30, 32 and 66, which all contain a diarylmethane group that is
common amongst inhibitors of various ion channels (e.g. ﬂunarizine,
diphenhydramine and chlorphenoxamine). However, these hits also
turned out to be poor starting points for elaboration (Table 3C), which
could be due to the possibility of diarylmethane-containing molecules
having a precedence of forming aggregates in solution, leading to
changes in their absorption properties (Attwood, 1976). For compounds
such as 41, 48 and 64 poor solubility might also be an explanation,
although no obvious precipitate was seen during our experiments.
A number of hits from the IOTA fragment library also demonstrated
activity when screened against hP2X1, namely 20, 35, 38, 64 and 66.
Similar to the search for hP2X4 ligands, these hits did not produce any
convincing SAR, and as they do not contain any structural elements
known to produce assay-interference, it is possible that they have non-
speciﬁc eﬀects. Following this failure to identify robust hits, re-
presentatives of structural chemotypes not represented within the li-
brary were also tested on hP2X1. Initial results were encouraging for a
series of biguanides where robust and reproducible inhibition was seen
using TEVC, and consequently it was possible to measure IC50 values for
several of these compounds (Table 4). Indeed, such compounds also
show activity at other ligand-gated ion channels (Lochner and
Thompson, 2014). However, despite obtaining consistent results these
compounds did not show consistent SAR that could be used for further
elaboration. Again it is diﬃcult to explain why hits could not be con-
verted into a robust series, although one possibility is that biguanides
are well documented to bind metal ions and their strongly interaction
with calcium may cause a variety of cellular eﬀects (Logie et al., 2012).
Our study struggled to identify consistent SAR. Furthermore, the
complex pharmacology and chemical nature of reported P2X4 and
P2X1 ligands does not align with currently accepted ‘drug like’ che-
mical space. In contrast to other members of the P2X receptor family,
there is also a paucity of high quality drug like compounds reported to
modulate P2X1 or P2X4 activity. For P2X4 these are generally of poor
quality, while the only molecules reported to have any interaction with
P2X1 are high molecular weight and promiscuous agents such as sur-
amin. These P2X1-active compounds also typically have high lipophi-
licity that frequently leads to a poor solubility, and is often highlighted
as a challenge in medicinal chemistry reviews (Gum et al., 2012;
Jacobson and Muller, 2016). Also, whilst it is not disclosed, their
physical chemistry suggests that it is highly likely that these existing
P2X-active compounds have poor pharmacokinetic proﬁles. For
Table 3E (continued)
Identiﬁer I/Imax n Structure
187 0.86 ± 0.06 3
188 0.90 ± 0.05 3
189 1.02 ± 0.12 3
190 0.68 ± 0.05 3
191 0.80 ± 0.01 3
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Table 4
Concentration-dependent actions of compounds tested using TEVC on oocyte-expressed hP2X1.
Compound pIC50 IC50 (mM) n Structure
192 (Proguanil) 2.95 ± 0.05 1.1 5
193 (mCPBG) 2.93 ± 0.05 1.2 5
194 3.22 ± 0.06 1.1 5
195 2.40 ± 0.03 4.0 4
196 3.42 ± 0.06 0.38 5
197 2.70 ± 0.08 2.0 5
198 3.37 ± 0.06 0.42 3
199 NE - 3
200 1.81 ± 0.01 15.4 3
201 2.57 ± 0.20 2.7 3
202 1.93 ± 0.15 11.7 3
203 NE - 3
204 NE - 4
205 NE - 3
(continued on next page)
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Table 4 (continued)
Compound pIC50 IC50 (mM) n Structure
206 3.50 ± 0.04 0.32 7
207 3.20 ± 0.03 0.63 3
208 (Metformin) NE - 3
209 NE - 7
210 2.39 ± 0.03 4.1 5
211 NE - 3
212 NE -
213 NE - 3
214 NE - 3
215 NE - 3
216 3.98 ± 0.05 0.10 3
217 NE - 3
218 2.92 ± 0.11 1.2 5
219 1.09 ± 0.09 81.3 3
220 NE - 3
221 2.73 ± 0.06 1.9 3
(continued on next page)
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example, Nippon Chemiphar have been pioneers in this area and have
identiﬁed structures such as UoS14919 and NP-1815_PX (Fig. 1)(Ush-
ioda, Kobayashi, Saito, Sakuma, Imai & Inoue). In the publication de-
scribing these structures they highlight the poor solubility of
UoS14919, and report that despite having slightly improved solubility,
NP-1815_PX is not suitable for oral administration and that intra thecal-
dosing has to be employed for in vivo testing (Matsumura et al., 2016).
As a result, only two molecules are reported to have entered develop-
ment despite many years of work. This includes NC600 which is de-
scribed by Nippon Chemiphar as having entered phase 1 studies in June
2016 (communication on company website), and more recently by
Bayer who announced they had entered the clinic with an unspeciﬁed
P2X4 antagonist (communication on company website). It is note-
worthy that only Nippon Chemiphar has reported the progression of a
molecule past the stage of the preliminary tests that would be applied
during the discovery phase of a project, and their molecules do appear
to have an encouraging proﬁle despite the poor physicochemical
properties. The lack of progression of any other reported compounds
suggests unreported challenges. The results we report here are con-
sistent with these diﬃculties, and highlight the importance of vali-
dating hit compounds using a range of pharmacological methods.
In our hands, established P2X ligands such as suramin and NF-449
caused inhibition of both FMA and TEVC responses at expected con-
centrations, as did UoS14919 (Ushioda, Kobayashi, Saito, Sakuma, Imai
& Inoue). In contrast, we were unable to observe pharmacological ac-
tivities with phenoxazine or acridinol, compounds that have been re-
ported as active following screening of phenoxazine and acridone de-
rivatives using ﬂuorescence-based calcium measurements (Hernandez-
Olmos et al., 2012). This ﬁnding highlights the challenges of identifying
P2X ligands and suggests that diﬀerent methods may yield conﬂicting
results. The lack of activity in our FMA and TEVC assays suggests these
compounds may have been false-positives in the calcium-based
Table 4 (continued)
Compound pIC50 IC50 (mM) n Structure
222 3.49 ± 0.04 0.32 3
223 2.95 ± 0.05 1.1 3
224 NE - 3
225 3.42 ± 0.04 0.38 3
226 2.36 ± 0.04 4.3 3
227 3.40 ± 0.08 0.40 3
Fig. 5. Concentration-dependent inhibition of the
hP2X1 response measured using TEVC. Example
concentration-response relationships are shown for
196 (A) and 216 (B). Parameters derived from these
curves can be found in Table 4. Inset is an example
trace showing the hP2X1 response to 0.5 μM ATP
(EC50: black horizontal bar).
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ﬂuorescence assays (Hernandez-Olmos et al., 2012). One possible
reason for this could be that the compounds identiﬁed by calcium-based
ﬂuorescence were pre-applied. However, even when we used pre-in-
cubation in our assays no inhibition was seen, showing that this is not
the case. It is also possible that the calcium-based ﬂuorescence assays
reported eﬀects on responses mediated by other cell-surface receptors,
or by mobilisation of intracellular stores. Indeed, using our voltage-
sensitive dye, we noted that 35 caused a depolarisation that was later
identiﬁed as a non-speciﬁc eﬀect with TEVC. For both carbamazepine
and paroxetine there is already literature evidence that demonstrates
they may result in calcium entry into various cell types (Pan et al. 2010;
von Borstel Smith, Crofoot, Rodriguez-Proteau & Filtz, 2007). The
structural similarity of the 9(10H)-acridanone and phenoxazine based
inhibitors to carbamazepine suggests that they could also aﬀect calcium
entry. Compounds such as carbamazepine, 9(10H)-acridanone and
phenoxazine also all share aromatic structures that will demonstrate
absorbance and could interfere with ﬂuorescence-based measurements.
For other ligand-gated ion channels a combination of functional
assays and ligand binding has been used to corroborate ligand actions.
Examples can include two or more approaches such as electro-
physiology, radioligand binding, surface plasmon resonance and ﬂow
cytometry, or by conﬁrming the binding of ligands by mutagenesis of
the target receptor (Lochner and Thompson, 2015). To date there are
few reports of P2X4 or P2X1 ligands that have been assessed by mul-
tiple methods. An exception is the study by (Hernandez-Olmos et al.,
2012) which revealed activity in calcium-based ﬂuorescence assays and
followed these up with radioligand competition assays. However, as no
competition was observed with radiolabelled ATP it was concluded that
the ligands were non-competitive at the orthosteric site, rather than
non-speciﬁc. In contrast, where complementary assays have instead
given consistent results across diﬀering assay formats, the actions of the
resultant ligands have been reproducible (Ase et al., 2015). Both our
own studies and this published evidence suggest that veriﬁcation of
potential hits by complimentary methods is needed to provide sup-
porting evidence of their eﬀects and that methods should be sought that
yield conﬁrmation of ligand activities.
The results presented here describe the identiﬁcation of low aﬃnity
ligands acting at hP2X4 and hP2X1 receptors. The activities that we
measured were too low to be of any pharmacological value, but their
structures might provide starting points for further elaboration or as
substructures in much larger ligands. Our results also highlight the
challenges of achieving consistent results across diﬀerent assay formats.
Such ﬁndings appear relatively common within the P2X ﬁeld. Ideally,
all future studies would therefore include a range of methods to vali-
date hits. This might include a means of identifying the binding site for
compounds and competition-based reporter assays to increase con-
ﬁdence in the results.
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